• Asbestos Exposure, Mesothelioma Litigation Trends Focus of California Conference
  • November 25, 2016
  • Law Firm: Waters Kraus LLP - Dallas Office
  • Co-Chair Michael Armitage: Conference occurs at important time for asbestos-exposure mesothelioma litigation

    LOS ANGELES - Top asbestos-exposure litigators from both sides of the bar and judges who have presided over some of the most important recent asbestos-related mesothelioma cancer trials are gathering in Los Angeles to review litigation trends, trial techniques and the science at the core of mesothelioma cancer litigation.

    Grave health threats associated with asbestos exposure to workers in traditional industrial, construction and maritime trades along with mounting incidents of deadly asbestos exposure from consumer products made with talc make the the Dec. 7 HarrisMartin California Litigation Conference critically important, says conference co-chair Michael L. Armitage, a partner with Waters Kraus & Paul.

    “This is an opportunity for trial lawyers who work day in and day out representing mesothelioma victims to take a broader look at the legal, medical and legislative trends affecting their clients,” Mr. Armitage said. “We hope to share our best practices so that we can make sure we are doing everything possible to get justice for hard-working Americans who have been exposed to asbestos.”

    More informaton about HarrisMartin’s California Asbestos Litigation Conference can be found here: http://harrismartin.com/conference/911/CalifAsb&under;Dec2016/

    A partner in the Los Angeles offices of Waters Kraus & Paul, Mr. Armitage is a leading asbestos litigator with a national practice. His work on behalf of plaintiffs in asbestos-related cancer cases has resulted in some of the firm’s most notable jury verdicts and settlements.

    This year’s conference will include highlights of notable cases and important developments over the previous year. In addition, a panel of three California judges will provide judicial perspectives gleaned from involvement in mesothelioma trials, while additional sessions will focus on cutting edge trial science techniques and appellate strategies.